胰腺神经内分泌瘤 G3 病例对化疗有显著反应。
A Case of Pancreatic Neuroendocrine Tumor G3 Which Responded Remarkably to Chemotherapy.
机构信息
Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan.
Department of Pathology and Cell Biology, School of Medicine, University of Occupational and Environmental Health, Japan.
出版信息
J UOEH. 2022;44(3):287-292. doi: 10.7888/juoeh.44.287.
Pancreatic neuroendocrine carcinoma (NEC) as classified in the World Health Organization (WHO) 2010 was reclassified in the WHO 2017 as either neuroendocrine tumor (NET) G3 or NEC. An accurate diagnosis based on the WHO 2017 classification is important in order treating this disease appropriately. We report a case diagnosed as NET G3 that responded remarkably well to treatment with streptozocin. The patient would likely not have received the streptozocin treatment if she had been diagnosed with NEC. The WHO 2017 classification is reasonable for the treatment of advanced pancreatic neuroendocrine neoplasms.
胰腺神经内分泌癌（NEC）在世界卫生组织（WHO）2010 年的分类中被重新分类为神经内分泌肿瘤（NET）G3 或 NEC。基于 WHO 2017 分类的准确诊断对于适当治疗这种疾病很重要。我们报告了一例被诊断为 NET G3 的病例，该病例对链脲佐菌素治疗反应良好。如果该患者被诊断为 NEC，她可能不会接受链脲佐菌素治疗。WHO 2017 分类对于治疗晚期胰腺神经内分泌肿瘤是合理的。
Zotero 插件